1. Home
  2. CHEK vs VIRX Comparison

CHEK vs VIRX Comparison

Compare CHEK & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHEK
  • VIRX
  • Stock Information
  • Founded
  • CHEK 2004
  • VIRX 2007
  • Country
  • CHEK Israel
  • VIRX United States
  • Employees
  • CHEK N/A
  • VIRX N/A
  • Industry
  • CHEK Medical Electronics
  • VIRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHEK Health Care
  • VIRX Health Care
  • Exchange
  • CHEK Nasdaq
  • VIRX Nasdaq
  • Market Cap
  • CHEK 9.0M
  • VIRX 6.8M
  • IPO Year
  • CHEK 2015
  • VIRX N/A
  • Fundamental
  • Price
  • CHEK $0.93
  • VIRX $0.08
  • Analyst Decision
  • CHEK
  • VIRX Buy
  • Analyst Count
  • CHEK 0
  • VIRX 4
  • Target Price
  • CHEK N/A
  • VIRX $5.00
  • AVG Volume (30 Days)
  • CHEK 78.9K
  • VIRX 2.1M
  • Earning Date
  • CHEK 02-18-2025
  • VIRX 03-06-2025
  • Dividend Yield
  • CHEK N/A
  • VIRX N/A
  • EPS Growth
  • CHEK N/A
  • VIRX N/A
  • EPS
  • CHEK N/A
  • VIRX N/A
  • Revenue
  • CHEK N/A
  • VIRX N/A
  • Revenue This Year
  • CHEK N/A
  • VIRX N/A
  • Revenue Next Year
  • CHEK N/A
  • VIRX N/A
  • P/E Ratio
  • CHEK N/A
  • VIRX N/A
  • Revenue Growth
  • CHEK N/A
  • VIRX N/A
  • 52 Week Low
  • CHEK $0.56
  • VIRX $0.07
  • 52 Week High
  • CHEK $3.45
  • VIRX $1.31
  • Technical
  • Relative Strength Index (RSI)
  • CHEK 42.16
  • VIRX 20.79
  • Support Level
  • CHEK $0.81
  • VIRX $0.14
  • Resistance Level
  • CHEK $1.00
  • VIRX $0.19
  • Average True Range (ATR)
  • CHEK 0.10
  • VIRX 0.02
  • MACD
  • CHEK -0.05
  • VIRX -0.01
  • Stochastic Oscillator
  • CHEK 13.98
  • VIRX 0.00

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About VIRX Viracta Therapeutics Inc.

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Share on Social Networks: